Adial Pharmaceuticals, Inc.

ADIL · NASDAQ

ADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.

Follow Add to Watchlist Ask Question

NASDAQ ADIL Coverage Bootstrap Biotechnology Addiction Medicine Alcohol Use Disorder

Latest ReportMay 14, 2026Adial Pharmaceuticals: the cheek-swab alcohol-use pill racing a 2026 runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.